This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

RBCC Scouts New Biotech Innovations At NIBA Investment Conference

Rainbow Coral Corp. (OTCBB: RBCC) executives will be on hand this week at the 124 th National Investment Banking Association (NIBA) Investment Conference in Las Vegas to seek out new partnership opportunities in the red-hot biotechnology sector.

The conference offers a chance for public and private companies to make formal presentations to corporations such as RBCC biotech subsidiary Rainbow Biosciences that are interested in new innovations ripe for capital investment.

“We’re particularly interested in discovering additional projects that exhibit short paths to marketability,” said RBCC CEO Patrick Brown. “We look forward to networking with hungry entrepreneurs and emerging businesses with the potential to grow our base of assets and increase shareholder value.”

RBCC is already hard at work helping to bring incredible new healthcare technologies to new markets. The company’s joint venture partner, Nano3D BioSciences (n3D) has developed a revolutionary 3D cell-culturing system that could soon lead to a breakthrough in cancer research. RBCC has also finalized joint venture terms with Amarantus BioSciences (OTCBB: AMBS), makers of a ground-breaking new blood-test diagnostic for Parkinson’s disease.

The company hopes to add to its portfolio of projects for commercialization at this week’s NIBA conference.

Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC) and Abbott Laboratories (NYSE: ABT).

For more information on Rainbow BioSciences, please visit

Follow us on Twitter at

About Rainbow BioSciences

Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at For investment information and performance data on the company, please visit

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs